drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00215 | DB06603 | 1,230 | 39 | [
"DDInter388",
"DDInter1387"
] | Citalopram | Panobinostat | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
1230,
25,
39
]
],
[
[
1230,
23,
112
],
[
112,
23,
39
]
],
[
[
1230,
24,
272
],
[
272,
24,
39
]
],
[
[
1230,
25,
506
],
[
506,
24... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine ... |
DB00193 | DB00281 | 534 | 608 | [
"DDInter1841",
"DDInter1066"
] | Tramadol | Lidocaine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication . In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anes... | Major | 2 | [
[
[
534,
25,
608
]
],
[
[
534,
6,
8374
],
[
8374,
45,
608
]
],
[
[
534,
21,
28722
],
[
28722,
60,
608
]
],
[
[
534,
25,
868
],
[
868,
... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lidocaine"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lidocaine"
... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lidocaine (Compound)
Tramadol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lidocaine (Compound)
Tramadol may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a minor in... |
DB00683 | DB01205 | 1,382 | 1,404 | [
"DDInter1212",
"DDInter748"
] | Midazolam | Flumazenil | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. | Moderate | 1 | [
[
[
1382,
24,
1404
]
],
[
[
1382,
6,
13500
],
[
13500,
45,
1404
]
],
[
[
1382,
21,
29003
],
[
29003,
60,
1404
]
],
[
[
1382,
1,
902
],
[
9... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flumazenil"
]
],
[
[
"Midazolam",
"{u} (Compound) binds {v} (Gene)",
"GABRA5"
],
[
"GABRA5",
"{u} (Gene) is bound by {v} (Compound)",
... | Midazolam (Compound) binds GABRA5 (Gene) and GABRA5 (Gene) is bound by Flumazenil (Compound)
Midazolam (Compound) causes Aggression (Side Effect) and Aggression (Side Effect) is caused by Flumazenil (Compound)
Midazolam (Compound) resembles Clobazam (Compound) and Clobazam may cause a moderate interaction that could ex... |
DB00290 | DB01206 | 329 | 37 | [
"DDInter219",
"DDInter1086"
] | Bleomycin | Lomustine | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | An alkylating agent of value against both hematologic malignancies and solid tumors. | Moderate | 1 | [
[
[
329,
24,
37
]
],
[
[
329,
5,
11555
],
[
11555,
44,
37
]
],
[
[
329,
21,
28722
],
[
28722,
60,
37
]
],
[
[
329,
62,
1176
],
[
1176,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
]
],
[
[
"Bleomycin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) ... | Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound)
Bleomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Lomustine (Compound)
Bleomycin may cause a minor interaction that can limit clinical effects when taken with... |
DB00092 | DB01101 | 58 | 60 | [
"DDInter40",
"DDInter285"
] | Alefacept | Capecitabine | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
58,
24,
60
]
],
[
[
58,
24,
309
],
[
309,
62,
60
]
],
[
[
58,
24,
147
],
[
147,
23,
60
]
],
[
[
58,
24,
713
],
[
713,
63,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinbl... |
DB01220 | DB08880 | 1,088 | 1,510 | [
"DDInter1593",
"DDInter1771"
] | Rifaximin | Teriflunomide | Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduc... | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Moderate | 1 | [
[
[
1088,
24,
1510
]
],
[
[
1088,
24,
129
],
[
129,
63,
1510
]
],
[
[
1088,
63,
279
],
[
279,
24,
1510
]
],
[
[
1088,
24,
1155
],
[
1155,
... | [
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[... | Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and ... |
DB00734 | DB06589 | 1,664 | 1,250 | [
"DDInter1605",
"DDInter1400"
] | Risperidone | Pazopanib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
1664,
24,
1250
]
],
[
[
1664,
6,
4973
],
[
4973,
45,
1250
]
],
[
[
1664,
21,
29264
],
[
29264,
60,
1250
]
],
[
[
1664,
23,
112
],
[
11... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Risperidone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Pazopanib (Compound)
Risperidone (Compound) causes Rhinorrhoea (Side Effect) and Rhinorrhoea (Side Effect) is caused by Pazopanib (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00218 | DB09122 | 1,176 | 1,613 | [
"DDInter1247",
"DDInter1409"
] | Moxifloxacin | Peginterferon beta-1a | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1176,
24,
1613
]
],
[
[
1176,
64,
600
],
[
600,
24,
1613
]
],
[
[
1176,
24,
1274
],
[
1274,
24,
1613
]
],
[
[
1176,
25,
351
],
[
351,
... | [
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
... | Moxifloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Fl... |
DB06589 | DB11652 | 1,250 | 1,155 | [
"DDInter1400",
"DDInter1891"
] | Pazopanib | Tucatinib | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Major | 2 | [
[
[
1250,
25,
1155
]
],
[
[
1250,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
1250,
64,
1424
],
[
1424,
24,
1155
]
],
[
[
1250,
24,
659
],
[
659... | [
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Pazopanib may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate ... |
DB11110 | DB11986 | 603 | 484 | [
"DDInter1115",
"DDInter648"
] | Magnesium citrate | Entrectinib | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
603,
24,
484
]
],
[
[
603,
63,
1539
],
[
1539,
24,
484
]
],
[
[
603,
24,
180
],
[
180,
63,
484
]
],
[
[
603,
24,
927
],
[
927,
2... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Olicerid... |
DB11560 | DB12941 | 1,678 | 466 | [
"DDInter1038",
"DDInter481"
] | Lesinurad | Darolutamide | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Moderate | 1 | [
[
[
1678,
24,
466
]
],
[
[
1678,
63,
1374
],
[
1374,
23,
466
]
],
[
[
1678,
24,
351
],
[
351,
23,
466
]
],
[
[
1678,
24,
159
],
[
159,
... | [
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
]
],
[
[
"Lesinurad",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Lesinurad may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Riboci... |
DB01149 | DB08895 | 851 | 976 | [
"DDInter1274",
"DDInter1825"
] | Nefazodone | Tofacitinib | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
851,
25,
976
]
],
[
[
851,
25,
214
],
[
214,
63,
976
]
],
[
[
851,
63,
86
],
[
86,
24,
976
]
],
[
[
851,
24,
407
],
[
407,
63,
... | [
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"... | Nefazodone may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may c... |
DB00836 | DB09080 | 543 | 144 | [
"DDInter1088",
"DDInter1331"
] | Loperamide | Olodaterol | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
543,
24,
144
]
],
[
[
543,
24,
956
],
[
956,
24,
144
]
],
[
[
543,
63,
695
],
[
695,
24,
144
]
],
[
[
543,
74,
11
],
[
11,
24,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Cloza... |
DB00902 | DB09038 | 104 | 1,450 | [
"DDInter1168",
"DDInter636"
] | Methdilazine | Empagliflozin | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
104,
24,
1450
]
],
[
[
104,
63,
461
],
[
461,
24,
1450
]
],
[
[
104,
24,
1551
],
[
1551,
24,
1450
]
],
[
[
104,
40,
9
],
[
9,
24... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa and Methy... |
DB00985 | DB09488 | 1,443 | 103 | [
"DDInter562",
"DDInter23"
] | Dimenhydrinate | Acrivastine | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1443,
24,
103
]
],
[
[
1443,
63,
85
],
[
85,
24,
103
]
],
[
[
1443,
24,
1264
],
[
1264,
24,
103
]
],
[
[
1443,
40,
357
],
[
357,
... | [
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Dimenhydrinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
... | Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Dimenhydrinate may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxe... |
DB00280 | DB00983 | 494 | 480 | [
"DDInter575",
"DDInter776"
] | Disopyramide | Formoterol | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
494,
24,
480
]
],
[
[
494,
25,
1148
],
[
1148,
63,
480
]
],
[
[
494,
21,
28719
],
[
28719,
60,
480
]
],
[
[
494,
24,
870
],
[
870,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isop... | Disopyramide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Disopyramide (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Formoterol (Compound)
Disopyramide ... |
DB00881 | DB01240 | 954 | 885 | [
"DDInter1554",
"DDInter657"
] | Quinapril | Epoprostenol | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
954,
24,
885
]
],
[
[
954,
63,
1061
],
[
1061,
1,
885
]
],
[
[
954,
21,
28936
],
[
28936,
60,
885
]
],
[
[
954,
63,
1512
],
[
1512,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Quinapril (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Quinapril may cause a moderate... |
DB00063 | DB00086 | 366 | 1,167 | [
"DDInter659",
"DDInter1712"
] | Eptifibatide | Streptokinase | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Major | 2 | [
[
[
366,
25,
1167
]
],
[
[
366,
23,
539
],
[
539,
62,
1167
]
],
[
[
366,
24,
992
],
[
992,
63,
1167
]
],
[
[
366,
25,
1317
],
[
1317,
... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptokinase"
]
],
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicu... | Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Streptokinase
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Ginger and Ginger may ... |
DB00370 | DB11113 | 1,251 | 657 | [
"DDInter1230",
"DDInter307"
] | Mirtazapine | Castor oil | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1251,
24,
657
]
],
[
[
1251,
24,
927
],
[
927,
63,
657
]
],
[
[
1251,
25,
985
],
[
985,
24,
657
]
],
[
[
1251,
63,
1181
],
[
1181,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Mirtazapine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may ... |
DB06282 | DB11915 | 516 | 1,293 | [
"DDInter1053",
"DDInter1909"
] | Levocetirizine | Valbenazine | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Valbenazine is a modified metabolite of [tetrabenazine], and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease.[L47885,A261135] Tardive dyskinesia has long been regarded as a consequence of anti-dopamine recept... | Moderate | 1 | [
[
[
516,
24,
1293
]
],
[
[
516,
63,
401
],
[
401,
24,
1293
]
],
[
[
516,
24,
407
],
[
407,
24,
1293
]
],
[
[
516,
63,
1053
],
[
1053,
... | [
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium an... |
DB00372 | DB00782 | 999 | 1,123 | [
"DDInter1793",
"DDInter1535"
] | Thiethylperazine | Propantheline | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
999,
24,
1123
]
],
[
[
999,
24,
359
],
[
359,
62,
1123
]
],
[
[
999,
24,
1577
],
[
1577,
23,
1123
]
],
[
[
999,
24,
768
],
[
768,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazi... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Propantheline
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB06288 | DB13074 | 607 | 877 | [
"DDInter77",
"DDInter1110"
] | Amisulpride | Macimorelin | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
607,
25,
877
]
],
[
[
607,
62,
112
],
[
112,
23,
877
]
],
[
[
607,
25,
913
],
[
913,
24,
877
]
],
[
[
607,
24,
1662
],
[
1662,
2... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Amisulpride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Amisulpride may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may... |
DB04868 | DB11732 | 478 | 1,097 | [
"DDInter1293",
"DDInter1027"
] | Nilotinib | Lasmiditan | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
478,
24,
1097
]
],
[
[
478,
64,
1181
],
[
1181,
24,
1097
]
],
[
[
478,
25,
971
],
[
971,
63,
1097
]
],
[
[
478,
63,
1413
],
[
1413,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine... | Nilotinib may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Nilotinib may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate ... |
DB00264 | DB06705 | 88 | 1,106 | [
"DDInter1200",
"DDInter795"
] | Metoprolol | Gadofosveset trisodium | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of th... | Moderate | 1 | [
[
[
88,
24,
1106
]
],
[
[
88,
63,
457
],
[
457,
40,
1106
]
],
[
[
88,
24,
796
],
[
796,
40,
1106
]
],
[
[
88,
21,
28644
],
[
28644,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadofosveset trisodium"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadodiamide"
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide and Gadodiamide (Compound) resembles Gadofosveset trisodium (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid and Gadoxetic acid (Compound) resembles ... |
DB06077 | DB09280 | 879 | 1,604 | [
"DDInter1102",
"DDInter1101"
] | Lumateperone | Lumacaftor | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Major | 2 | [
[
[
879,
25,
1604
]
],
[
[
879,
24,
292
],
[
292,
24,
1604
]
],
[
[
879,
63,
473
],
[
473,
24,
1604
]
],
[
[
879,
64,
593
],
[
593,
... | [
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regor... | Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and... |
DB00491 | DB00774 | 127 | 1,577 | [
"DDInter1217",
"DDInter889"
] | Miglitol | Hydroflumethiazide | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
127,
24,
1577
]
],
[
[
127,
24,
359
],
[
359,
40,
1577
]
],
[
[
127,
63,
323
],
[
323,
40,
1577
]
],
[
[
127,
24,
504
],
[
504,
... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) re... |
DB00627 | DB00912 | 265 | 473 | [
"DDInter1286",
"DDInter1581"
] | Niacin | Repaglinide | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
265,
24,
473
]
],
[
[
265,
21,
28757
],
[
28757,
60,
473
]
],
[
[
265,
63,
1645
],
[
1645,
24,
473
]
],
[
[
265,
24,
433
],
[
433,
... | [
[
[
"Niacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Niacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {... | Niacin (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Repaglinide (Compound)
Niacin may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Niac... |
DB00816 | DB01210 | 1,674 | 668 | [
"DDInter1346",
"DDInter1050"
] | Orciprenaline | Levobunolol (ophthalmic) | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrener... | Major | 2 | [
[
[
1674,
25,
668
]
],
[
[
1674,
64,
461
],
[
461,
1,
668
]
],
[
[
1674,
24,
688
],
[
688,
25,
668
]
],
[
[
1674,
25,
887
],
[
887,
... | [
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levobunolol"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} ... | Orciprenaline may lead to a major life threatening interaction when taken with Levobunolol
Orciprenaline may lead to a major life threatening interaction when taken with Timolol and Timolol (Compound) resembles Levobunolol (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when tak... |
DB06372 | DB09330 | 259 | 985 | [
"DDInter1594",
"DDInter1352"
] | Rilonacept | Osimertinib | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
259,
24,
985
]
],
[
[
259,
63,
168
],
[
168,
23,
985
]
],
[
[
259,
63,
134
],
[
134,
24,
985
]
],
[
[
259,
24,
119
],
[
119,
63,... | [
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Rilonacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinore... |
DB00280 | DB08912 | 494 | 1,040 | [
"DDInter575",
"DDInter462"
] | Disopyramide | Dabrafenib | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
494,
24,
1040
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
494,
21,
28779
],
[
28779,
60,
1040
]
],
[
[
494,
24,
608
],
[
608,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Disopyramide (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Dabrafenib (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and... |
DB01136 | DB08938 | 772 | 1,384 | [
"DDInter305",
"DDInter1112"
] | Carvedilol | Magaldrate | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
772,
23,
1384
]
],
[
[
772,
63,
167
],
[
167,
23,
1384
]
],
[
[
772,
24,
1220
],
[
1220,
23,
1384
]
],
[
[
772,
63,
245
],
[
245,
... | [
[
[
"Carvedilol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Carvedilol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
... | Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone a... |
DB00563 | DB06589 | 663 | 1,250 | [
"DDInter1174",
"DDInter1400"
] | Methotrexate | Pazopanib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
663,
24,
1250
]
],
[
[
663,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
663,
7,
17088
],
[
17088,
46,
1250
]
],
[
[
663,
18,
4729
],
[
4729... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compou... | Methotrexate (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Methotrexate (Compound) upregulates ATP5S (Gene) and ATP5S (Gene) is upregulated by Pazopanib (Compound)
Methotrexate (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is upregulated by Pazopanib (Compound)
Metho... |
DB00860 | DB01199 | 891 | 1,217 | [
"DDInter1513",
"DDInter1890"
] | Prednisolone | Tubocurarine | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Tubocurarine is a non-depolarizing neuromuscular blocking agent and the first identified curare alkaloid. Curare is one of the names used to describe plant-derived poisons used by indigenous South Americans to coat the tips of hunting arrows and darts, which were typically derived from plants of the genera _Chondrodend... | Moderate | 1 | [
[
[
891,
24,
1217
]
],
[
[
891,
24,
545
],
[
545,
1,
1217
]
],
[
[
891,
40,
1573
],
[
1573,
24,
1217
]
],
[
[
891,
63,
1287
],
[
1287,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubocurarine"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metocurine"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Metocurine and Metocurine (Compound) resembles Tubocurarine (Compound)
Prednisolone (Compound) resembles Prednisone (Compound) and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Tuboc... |
DB00563 | DB09330 | 663 | 985 | [
"DDInter1174",
"DDInter1352"
] | Methotrexate | Osimertinib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Moderate | 1 | [
[
[
663,
24,
985
]
],
[
[
663,
63,
168
],
[
168,
23,
985
]
],
[
[
663,
24,
1247
],
[
1247,
23,
985
]
],
[
[
663,
24,
1478
],
[
1478,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole a... |
DB11348 | DB11799 | 1,065 | 627 | [
"DDInter279",
"DDInter205"
] | Calcium Phosphate | Bictegravir | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label]. | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Major | 2 | [
[
[
1065,
25,
627
]
],
[
[
1065,
63,
72
],
[
72,
24,
627
]
],
[
[
1065,
24,
943
],
[
943,
24,
1473
],
[
1473,
64,
627
]
],
[
[
1065,
... | [
[
[
"Calcium Phosphate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
],
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
... | Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Sare... |
DB00241 | DB09039 | 288 | 1,670 | [
"DDInter257",
"DDInter629"
] | Butalbital | Eliglustat | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
288,
24,
1670
]
],
[
[
288,
24,
1135
],
[
1135,
62,
1670
]
],
[
[
288,
24,
1409
],
[
1409,
24,
1670
]
],
[
[
288,
24,
124
],
[
124,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may... |
DB00681 | DB00736 | 1,287 | 660 | [
"DDInter85",
"DDInter676"
] | Amphotericin B | Esomeprazole | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Moderate | 1 | [
[
[
1287,
24,
660
]
],
[
[
1287,
63,
1215
],
[
1215,
40,
660
]
],
[
[
1287,
24,
379
],
[
379,
40,
660
]
],
[
[
1287,
63,
837
],
[
837,
... | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
... | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomep... |
DB08826 | DB12500 | 1,292 | 283 | [
"DDInter489",
"DDInter714"
] | Deferiprone | Fedratinib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1292,
25,
283
]
],
[
[
1292,
25,
351
],
[
351,
23,
283
]
],
[
[
1292,
64,
1419
],
[
1419,
24,
283
]
],
[
[
1292,
25,
1580
],
[
1580,
... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u}... | Deferiprone may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Deferiprone may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interact... |
DB00497 | DB09036 | 828 | 812 | [
"DDInter1366",
"DDInter1668"
] | Oxycodone | Siltuximab | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
828,
24,
812
]
],
[
[
828,
24,
259
],
[
259,
24,
812
]
],
[
[
828,
63,
1184
],
[
1184,
24,
812
]
],
[
[
828,
63,
1057
],
[
1057,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
... | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Siltuximab
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra m... |
DB00731 | DB01359 | 1,144 | 729 | [
"DDInter1269",
"DDInter1417"
] | Nateglinide | Penbutolol | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1144,
24,
729
]
],
[
[
1144,
63,
461
],
[
461,
1,
729
]
],
[
[
1144,
24,
699
],
[
699,
40,
729
]
],
[
[
1144,
6,
6943
],
[
6943,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Nateglinid... |
DB00106 | DB01254 | 618 | 1,213 | [
"DDInter4",
"DDInter484"
] | Abarelix | Dasatinib | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
618,
24,
1213
]
],
[
[
618,
23,
1247
],
[
1247,
23,
1213
]
],
[
[
618,
24,
479
],
[
479,
23,
1213
]
],
[
[
618,
24,
1133
],
[
1133,
... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Abarelix may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Done... |
DB00397 | DB09268 | 1,466 | 1,662 | [
"DDInter1458",
"DDInter1464"
] | Phenylpropanolamine | Picosulfuric acid | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1466,
24,
1662
]
],
[
[
1466,
24,
1482
],
[
1482,
23,
1662
]
],
[
[
1466,
63,
1252
],
[
1252,
23,
1662
]
],
[
[
1466,
24,
1164
],
[
11... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Di... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00705 | DB09073 | 441 | 951 | [
"DDInter496",
"DDInter1379"
] | Delavirdine | Palbociclib | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Major | 2 | [
[
[
441,
25,
951
]
],
[
[
441,
25,
1476
],
[
1476,
63,
951
]
],
[
[
441,
24,
710
],
[
710,
63,
951
]
],
[
[
441,
64,
467
],
[
467,
2... | [
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palbociclib"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u... | Delavirdine may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may c... |
DB00533 | DB00569 | 1,416 | 553 | [
"DDInter1613",
"DDInter775"
] | Rofecoxib | Fondaparinux | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Moderate | 1 | [
[
[
1416,
24,
553
]
],
[
[
1416,
63,
1560
],
[
1560,
24,
553
]
],
[
[
1416,
24,
298
],
[
298,
63,
553
]
],
[
[
1416,
24,
477
],
[
477,
... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Pro... |
DB00317 | DB08827 | 883 | 990 | [
"DDInter810",
"DDInter1085"
] | Gefitinib | Lomitapide | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Major | 2 | [
[
[
883,
25,
990
]
],
[
[
883,
24,
1080
],
[
1080,
1,
990
]
],
[
[
883,
6,
8374
],
[
8374,
45,
990
]
],
[
[
883,
21,
28903
],
[
28903,
... | [
[
[
"Gefitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
"Conivaptan",... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Gefitinib (Compound) causes Dry skin (Side Effect) and Dry skin (Sid... |
DB00604 | DB00782 | 1,425 | 1,123 | [
"DDInter385",
"DDInter1535"
] | Cisapride | Propantheline | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
1425,
24,
1123
]
],
[
[
1425,
25,
359
],
[
359,
62,
1123
]
],
[
[
1425,
64,
323
],
[
323,
23,
1123
]
],
[
[
1425,
25,
1577
],
[
1577,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorothiazide"
],
[
"Chlor... | Cisapride may lead to a major life threatening interaction when taken with Chlorothiazide and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Propantheline
Cisapride may lead to a major life threatening interaction when taken with Bendroflumethiazide and Bendroflumethiazide ... |
DB00450 | DB01344 | 78 | 1,231 | [
"DDInter603",
"DDInter1830"
] | Droperidol | Tolevamer | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Major | 2 | [
[
[
78,
25,
1231
]
],
[
[
78,
25,
870
],
[
870,
24,
1231
]
],
[
[
78,
24,
603
],
[
603,
63,
1231
]
],
[
[
78,
1,
1300
],
[
1300,
24,... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
... | Droperidol may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magne... |
DB00604 | DB12147 | 1,425 | 241 | [
"DDInter385",
"DDInter661"
] | Cisapride | Erdafitinib | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
1425,
24,
241
]
],
[
[
1425,
25,
384
],
[
384,
24,
241
]
],
[
[
1425,
25,
982
],
[
982,
63,
241
]
],
[
[
1425,
24,
467
],
[
467,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib"... | Cisapride may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Cisapride may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate inter... |
DB01390 | DB06616 | 1,117 | 594 | [
"DDInter1683",
"DDInter224"
] | Sodium bicarbonate | Bosutinib | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
1117,
24,
594
]
],
[
[
1117,
21,
28709
],
[
28709,
60,
594
]
],
[
[
1117,
62,
1559
],
[
1559,
24,
594
]
],
[
[
1117,
24,
786
],
[
786,... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Sodium bicarbonate",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",... | Sodium bicarbonate (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate d... |
DB03404 | DB09030 | 765 | 840 | [
"DDInter855",
"DDInter1945"
] | Hemin | Vorapaxar | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Moderate | 1 | [
[
[
765,
24,
840
]
],
[
[
765,
63,
383
],
[
383,
24,
840
]
],
[
[
765,
24,
1496
],
[
1496,
63,
840
]
],
[
[
765,
24,
578
],
[
578,
2... | [
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
]
],
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Hemin may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Hemin may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib a... |
DB01267 | DB11110 | 519 | 603 | [
"DDInter1381",
"DDInter1115"
] | Paliperidone | Magnesium citrate | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
519,
24,
603
]
],
[
[
519,
64,
57
],
[
57,
24,
603
]
],
[
[
519,
24,
1616
],
[
1616,
24,
603
]
],
[
[
519,
63,
870
],
[
870,
24,... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Paliperidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Paliperidone may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and... |
DB00226 | DB06764 | 1,000 | 1,090 | [
"DDInter845",
"DDInter1788"
] | Guanadrel | Tetryzoline (ophthalmic) | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1000,
24,
1090
]
],
[
[
1000,
24,
1148
],
[
1148,
24,
1090
]
],
[
[
1000,
37,
247
],
[
247,
25,
1090
]
],
[
[
1000,
24,
1629
],
[
1629... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Guanad... |
DB00872 | DB01410 | 1,080 | 423 | [
"DDInter438",
"DDInter376"
] | Conivaptan | Ciclesonide (nasal) | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Ciclesonide is an organic molecular entity. | Moderate | 1 | [
[
[
1080,
24,
423
]
],
[
[
1080,
63,
1573
],
[
1573,
1,
423
]
],
[
[
1080,
63,
1351
],
[
1351,
40,
423
]
],
[
[
1080,
25,
1486
],
[
1486,
... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ciclesonide"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Ciclesonide
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Conivaptan may cause a moderate interaction that could e... |
DB11767 | DB14783 | 1,583 | 287 | [
"DDInter1643",
"DDInter574"
] | Sarilumab | Diroximel fumarate | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1583,
24,
287
]
],
[
[
1583,
63,
1560
],
[
1560,
24,
287
]
],
[
[
1583,
24,
270
],
[
270,
24,
287
]
],
[
[
1583,
64,
1394
],
[
1394,
... | [
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
... | Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab... |
DB00694 | DB01166 | 51 | 477 | [
"DDInter485",
"DDInter379"
] | Daunorubicin | Cilostazol | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
51,
24,
477
]
],
[
[
51,
6,
8374
],
[
8374,
45,
477
]
],
[
[
51,
18,
4450
],
[
4450,
46,
477
]
],
[
[
51,
18,
6509
],
[
6509,
57... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Daunorubicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Daunorubicin (Compound) downregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Cilostazol (Compound)
Daunorubicin (Compound) downregulates EIF5 (Gene) and EIF5 (Gene) is downregulated by Cilostazol (Compound)
Daunorubic... |
DB00270 | DB08865 | 1,428 | 1,593 | [
"DDInter993",
"DDInter448"
] | Isradipine | Crizotinib | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1428,
24,
1593
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
1428,
7,
10670
],
[
10670,
46,
1593
]
],
[
[
1428,
21,
29093
],
[
2... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Isradipine (Compound) upregulates KLHL21 (Gene) and KLHL21 (Gene) is upregulated by Crizotinib (Compound)
Isradipine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Isradipi... |
DB01076 | DB09272 | 700 | 412 | [
"DDInter133",
"DDInter632"
] | Atorvastatin | Eluxadoline | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
700,
24,
412
]
],
[
[
700,
63,
467
],
[
467,
24,
412
]
],
[
[
700,
24,
384
],
[
384,
24,
412
]
],
[
[
700,
40,
1080
],
[
1080,
2... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
],
... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and... |
DB00601 | DB09570 | 453 | 1,480 | [
"DDInter1073",
"DDInter1002"
] | Linezolid | Ixazomib | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
453,
24,
1480
]
],
[
[
453,
63,
268
],
[
268,
24,
1480
]
],
[
[
453,
24,
148
],
[
148,
63,
1480
]
],
[
[
453,
24,
310
],
[
310,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
],
... | Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Sec... |
DB00261 | DB12141 | 702 | 971 | [
"DDInter93",
"DDInter817"
] | Anagrelide | Gilteritinib | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
702,
25,
971
]
],
[
[
702,
23,
1247
],
[
1247,
23,
971
]
],
[
[
702,
25,
485
],
[
485,
24,
971
]
],
[
[
702,
25,
730
],
[
730,
6... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulf... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Anagrelide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidin... |
DB00794 | DB11995 | 759 | 1,634 | [
"DDInter1521",
"DDInter143"
] | Primidone | Avatrombopag | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
759,
24,
1634
]
],
[
[
759,
25,
760
],
[
760,
24,
1634
]
],
[
[
759,
1,
697
],
[
697,
24,
1634
]
],
[
[
759,
63,
254
],
[
254,
2... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat... | Primidone may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Primidone (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerba... |
DB06791 | DB14723 | 1,446 | 159 | [
"DDInter1021",
"DDInter1026"
] | Lanreotide | Larotrectinib | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1446,
24,
159
]
],
[
[
1446,
23,
907
],
[
907,
23,
159
]
],
[
[
1446,
24,
1375
],
[
1375,
24,
159
]
],
[
[
1446,
24,
1650
],
[
1650,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
... | Lanreotide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamuli... |
DB00420 | DB11837 | 508 | 1,297 | [
"DDInter1532",
"DDInter1351"
] | Promazine | Osilodrostat | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
508,
24,
1297
]
],
[
[
508,
23,
112
],
[
112,
23,
1297
]
],
[
[
508,
24,
222
],
[
222,
23,
1297
]
],
[
[
508,
1,
623
],
[
623,
2... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sib... |
DB00564 | DB01246 | 1,236 | 820 | [
"DDInter293",
"DDInter45"
] | Carbamazepine | Alimemazine | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
1236,
24,
820
]
],
[
[
1236,
24,
104
],
[
104,
40,
820
]
],
[
[
1236,
1,
1335
],
[
1335,
24,
820
]
],
[
[
1236,
24,
401
],
[
401,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Carbamazepine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00078 | DB00465 | 1,172 | 886 | [
"DDInter898",
"DDInter1011"
] | Ibritumomab tiuxetan | Ketorolac (ophthalmic) | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Ketorolac is a racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used... | Moderate | 1 | [
[
[
1172,
37,
886
]
],
[
[
1172,
24,
282
],
[
282,
40,
886
]
],
[
[
1172,
25,
24
],
[
24,
40,
886
]
],
[
[
1172,
64,
25
],
[
25,
24,... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate int... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketorolac
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Nepafena... |
DB00662 | DB01367 | 717 | 1,163 | [
"DDInter1873",
"DDInter1572"
] | Trimethobenzamide | Rasagiline | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
717,
24,
1163
]
],
[
[
717,
21,
28766
],
[
28766,
60,
1163
]
],
[
[
717,
24,
100
],
[
100,
24,
1163
]
],
[
[
717,
63,
701
],
[
701,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Si... | Trimethobenzamide (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Rasagiline (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate dise... |
DB00656 | DB11963 | 827 | 1,045 | [
"DDInter1851",
"DDInter465"
] | Trazodone | Dacomitinib | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Moderate | 1 | [
[
[
827,
24,
1045
]
],
[
[
827,
25,
1039
],
[
1039,
24,
1045
]
],
[
[
827,
24,
1376
],
[
1376,
24,
1045
]
],
[
[
827,
40,
695
],
[
695,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfen... | Trazodone may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenh... |
DB00366 | DB00564 | 1,594 | 1,236 | [
"DDInter600",
"DDInter293"
] | Doxylamine | Carbamazepine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
1594,
24,
1236
]
],
[
[
1594,
35,
1405
],
[
1405,
40,
1236
]
],
[
[
1594,
24,
508
],
[
508,
1,
1236
]
],
[
[
1594,
63,
362
],
[
362,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when take... | Doxylamine (Compound) resembles Cyclobenzaprine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Carbamazepine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when take... |
DB00747 | DB01142 | 1,442 | 1,264 | [
"DDInter1647",
"DDInter593"
] | Scopolamine | Doxepin | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1442,
24,
1264
]
],
[
[
1442,
63,
508
],
[
508,
24,
1264
]
],
[
[
1442,
24,
401
],
[
401,
24,
1264
]
],
[
[
1442,
24,
1405
],
[
1405,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prometh... |
DB01211 | DB06636 | 609 | 1,623 | [
"DDInter393",
"DDInter980"
] | Clarithromycin | Isavuconazonium | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Major | 2 | [
[
[
609,
25,
1623
]
],
[
[
609,
24,
466
],
[
466,
62,
1623
]
],
[
[
609,
62,
222
],
[
222,
23,
1623
]
],
[
[
609,
62,
1601
],
[
1601,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutram... |
DB00675 | DB00734 | 888 | 1,664 | [
"DDInter1744",
"DDInter1605"
] | Tamoxifen | Risperidone | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
888,
24,
1664
]
],
[
[
888,
25,
924
],
[
924,
40,
1664
]
],
[
[
888,
24,
519
],
[
519,
40,
1664
]
],
[
[
888,
6,
4973
],
[
4973,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidon... | Tamoxifen may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Risperidone (Compound)
Tamoxifen... |
DB04865 | DB06589 | 4 | 1,250 | [
"DDInter1335",
"DDInter1400"
] | Omacetaxine mepesuccinate | Pazopanib | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
4,
24,
1250
]
],
[
[
4,
7,
16971
],
[
16971,
45,
1250
]
],
[
[
4,
7,
2959
],
[
2959,
46,
1250
]
],
[
[
4,
18,
2049
],
[
2049,
46... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} (Compound) upregulates {v} (Gene)",
"RIOK2"
],
[
"RIOK2",
"{u} (G... | Omacetaxine mepesuccinate (Compound) upregulates RIOK2 (Gene) and RIOK2 (Gene) is bound by Pazopanib (Compound)
Omacetaxine mepesuccinate (Compound) upregulates MNAT1 (Gene) and MNAT1 (Gene) is upregulated by Pazopanib (Compound)
Omacetaxine mepesuccinate (Compound) downregulates MRPS16 (Gene) and MRPS16 (Gene) is upre... |
DB01044 | DB09038 | 246 | 1,450 | [
"DDInter809",
"DDInter636"
] | Gatifloxacin | Empagliflozin | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Major | 2 | [
[
[
246,
25,
1450
]
],
[
[
246,
64,
485
],
[
485,
24,
1450
]
],
[
[
246,
24,
659
],
[
659,
63,
1450
]
],
[
[
246,
1,
872
],
[
872,
2... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Empagliflozin"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
... | Gatifloxacin may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol m... |
DB00366 | DB01114 | 1,594 | 272 | [
"DDInter600",
"DDInter362"
] | Doxylamine | Chlorpheniramine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1594,
35,
272
]
],
[
[
1594,
24,
358
],
[
358,
63,
272
]
],
[
[
1594,
1,
11775
],
[
11775,
40,
272
]
],
[
[
1594,
40,
11244
],
[
11244... | [
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Doxylamine (Compound) resembles Chlorpheniramine (Compound) and
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Doxylamine (Compound) resembles Chloro... |
DB06441 | DB08886 | 936 | 637 | [
"DDInter283",
"DDInter126"
] | Cangrelor | Asparaginase Erwinia chrysanthemi | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
936,
24,
637
]
],
[
[
936,
63,
1274
],
[
1274,
24,
637
]
],
[
[
936,
25,
1421
],
[
1421,
63,
637
]
],
[
[
936,
64,
1018
],
[
1018,
... | [
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Cangrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbi... | Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Cangrelor may lead to a major life threatening interaction when taken with Betrixaban ... |
DB00041 | DB09156 | 1,648 | 777 | [
"DDInter38",
"DDInter964"
] | Aldesleukin | Iopromide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Moderate | 1 | [
[
[
1648,
24,
777
]
],
[
[
1648,
24,
772
],
[
772,
24,
777
]
],
[
[
1648,
24,
1013
],
[
1013,
63,
777
]
],
[
[
1648,
24,
372
],
[
372,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopromide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol and Carvedilol may cause a moderate interaction that could exacerbate diseases when taken with Iopromide
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and ... |
DB06754 | DB08918 | 707 | 41 | [
"DDInter471",
"DDInter1059"
] | Danaparoid | Levomilnacipran | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity tha... | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Moderate | 1 | [
[
[
707,
24,
41
]
],
[
[
707,
63,
901
],
[
901,
40,
41
]
],
[
[
707,
25,
498
],
[
498,
63,
41
]
],
[
[
707,
64,
330
],
[
330,
24,
... | [
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
... | Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Danaparoid may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate ... |
DB00382 | DB12267 | 62 | 1,476 | [
"DDInter1734",
"DDInter233"
] | Tacrine | Brigatinib | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
62,
24,
1476
]
],
[
[
62,
24,
79
],
[
79,
24,
1476
]
],
[
[
62,
63,
1010
],
[
1010,
24,
1476
]
],
[
[
62,
24,
1619
],
[
1619,
63... | [
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"So... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may... |
DB00055 | DB09075 | 834 | 498 | [
"DDInter605",
"DDInter621"
] | Drotrecogin alfa | Edoxaban | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
834,
25,
498
]
],
[
[
834,
23,
944
],
[
944,
62,
498
]
],
[
[
834,
24,
1004
],
[
1004,
63,
498
]
],
[
[
834,
24,
41
],
[
41,
24,... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Cha... | Drotrecogin alfa may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate... |
DB00983 | DB01132 | 480 | 1,130 | [
"DDInter776",
"DDInter1472"
] | Formoterol | Pioglitazone | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
480,
24,
1130
]
],
[
[
480,
6,
12523
],
[
12523,
45,
1130
]
],
[
[
480,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
480,
63,
307
],
[
307,... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Formoterol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)... | Formoterol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Formoterol (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases whe... |
DB00927 | DB01069 | 1,559 | 401 | [
"DDInter712",
"DDInter1533"
] | Famotidine | Promethazine | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1559,
24,
401
]
],
[
[
1559,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1559,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1559,
23,
460
],
[
460,... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Famotidine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Prom... |
DB00820 | DB06589 | 402 | 1,250 | [
"DDInter1736",
"DDInter1400"
] | Tadalafil | Pazopanib | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
402,
24,
1250
]
],
[
[
402,
6,
8374
],
[
8374,
45,
1250
]
],
[
[
402,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
402,
63,
1419
],
[
1419,... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Tadalafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tadalafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Tadalafil (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may ... |
DB01169 | DB01242 | 57 | 1,237 | [
"DDInter120",
"DDInter410"
] | Arsenic trioxide | Clomipramine | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Major | 2 | [
[
[
57,
25,
1237
]
],
[
[
57,
64,
684
],
[
684,
1,
1237
]
],
[
[
57,
64,
401
],
[
401,
24,
1237
]
],
[
[
57,
25,
9
],
[
9,
1,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clomipramine"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridaz... | Arsenic trioxide may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Arsenic trioxide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerb... |
DB00270 | DB09038 | 1,428 | 1,450 | [
"DDInter993",
"DDInter636"
] | Isradipine | Empagliflozin | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1428,
24,
1450
]
],
[
[
1428,
24,
1061
],
[
1061,
24,
1450
]
],
[
[
1428,
1,
84
],
[
84,
24,
1450
]
],
[
[
1428,
24,
1017
],
[
1017,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isradipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction t... |
DB08908 | DB11834 | 713 | 1,303 | [
"DDInter564",
"DDInter849"
] | Dimethyl fumarate | Guselkumab | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
713,
24,
1303
]
],
[
[
713,
24,
949
],
[
949,
24,
1303
]
],
[
[
713,
63,
58
],
[
58,
24,
1303
]
],
[
[
713,
25,
287
],
[
287,
63... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium t... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Dimet... |
DB00060 | DB00814 | 912 | 1,171 | [
"DDInter947",
"DDInter1143"
] | Interferon beta-1a | Meloxicam | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
912,
24,
1171
]
],
[
[
912,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
912,
63,
1560
],
[
1560,
24,
1171
]
],
[
[
912,
24,
1274
],
[
1274,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate inter... |
DB00063 | DB00285 | 366 | 1,100 | [
"DDInter659",
"DDInter1927"
] | Eptifibatide | Venlafaxine | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Moderate | 1 | [
[
[
366,
24,
1100
]
],
[
[
366,
24,
643
],
[
643,
40,
1100
]
],
[
[
366,
25,
235
],
[
235,
63,
1100
]
],
[
[
366,
25,
273
],
[
273,
... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) resembles Venlafaxine (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exa... |
DB00919 | DB09268 | 567 | 1,662 | [
"DDInter1706",
"DDInter1464"
] | Spectinomycin | Picosulfuric acid | An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
567,
24,
1662
]
],
[
[
567,
18,
7212
],
[
7212,
46,
702
],
[
702,
24,
1662
]
],
[
[
567,
21,
28778
],
[
28778,
60,
240
],
[
240,
24,... | [
[
[
"Spectinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Spectinomycin",
"{u} (Compound) downregulates {v} (Gene)",
"HMG20B"
],
[
"HMG20B",
"{u} (Gene) is upre... | Spectinomycin (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is upregulated by Anagrelide (Compound) and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Spectinomycin (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Ef... |
DB01087 | DB12245 | 1,520 | 823 | [
"DDInter1520",
"DDInter1863"
] | Primaquine | Triclabendazole | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1520,
24,
823
]
],
[
[
1520,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1520,
24,
1612
],
[
1612,
24,
823
]
],
[
[
1520,
63,
1010
],
[
1010,... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsa... |
DB00285 | DB00983 | 1,100 | 480 | [
"DDInter1927",
"DDInter776"
] | Venlafaxine | Formoterol | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1100,
24,
480
]
],
[
[
1100,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1100,
6,
6017
],
[
6017,
45,
480
]
],
[
[
1100,
21,
28963
],
[
28963... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Venlafaxine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Formoterol (Compound)
Venlafaxine ... |
DB01174 | DB06282 | 697 | 516 | [
"DDInter1442",
"DDInter1053"
] | Phenobarbital | Levocetirizine | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
697,
24,
516
]
],
[
[
697,
63,
1031
],
[
1031,
23,
516
]
],
[
[
697,
63,
701
],
[
701,
24,
516
]
],
[
[
697,
40,
157
],
[
157,
2... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastin... |
DB00619 | DB09083 | 1,419 | 880 | [
"DDInter909",
"DDInter996"
] | Imatinib | Ivabradine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1419,
25,
880
]
],
[
[
1419,
25,
1478
],
[
1478,
24,
880
]
],
[
[
1419,
24,
159
],
[
159,
63,
880
]
],
[
[
1419,
24,
1040
],
[
1040,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cau... | Imatinib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause ... |
DB00675 | DB00836 | 888 | 543 | [
"DDInter1744",
"DDInter1088"
] | Tamoxifen | Loperamide | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
888,
24,
543
]
],
[
[
888,
1,
11392
],
[
11392,
40,
543
]
],
[
[
888,
64,
675
],
[
675,
24,
543
]
],
[
[
888,
40,
649
],
[
649,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl Acetate"
],
[
"Methadyl Acetate",
"{u} (Compound... | Tamoxifen (Compound) resembles Methadyl Acetate (Compound) and Methadyl Acetate (Compound) resembles Loperamide (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB01157 | DB11627 | 304 | 1,367 | [
"DDInter1875",
"DDInter860"
] | Trimetrexate | Hepatitis B Vaccine (Recombinant) | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
304,
24,
1367
]
],
[
[
304,
63,
1560
],
[
1560,
24,
1367
]
],
[
[
304,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
304,
24,
259
],
[
259,
... | [
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Trimetrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Trimetrexate may lead to a major life threatening interaction when taken with Cladr... |
DB00195 | DB06709 | 726 | 592 | [
"DDInter198",
"DDInter1165"
] | Betaxolol (ophthalmic) | Methacholine | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying patholo... | Major | 2 | [
[
[
726,
25,
592
]
],
[
[
726,
21,
28644
],
[
28644,
60,
592
]
],
[
[
726,
1,
88
],
[
88,
25,
592
]
],
[
[
726,
21,
28644
],
[
28644,
... | [
[
[
"Betaxolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methacholine"
]
],
[
[
"Betaxolol",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound... | Betaxolol may lead to a major life threatening interaction when taken with Methacholine
Betaxolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Methacholine (Compound)
Betaxolol (Compound) resembles Metoprolol (Compound) and Metoprolol may lead to a major life threatening interaction wh... |
DB04911 | DB12015 | 968 | 1,033 | [
"DDInter1347",
"DDInter53"
] | Oritavancin | Alpelisib | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
968,
24,
1033
]
],
[
[
968,
24,
760
],
[
760,
24,
1033
]
],
[
[
968,
63,
126
],
[
126,
24,
1033
]
],
[
[
968,
62,
168
],
[
168,
... | [
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
... | Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfari... |
DB00370 | DB00675 | 1,251 | 888 | [
"DDInter1230",
"DDInter1744"
] | Mirtazapine | Tamoxifen | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
1251,
24,
888
]
],
[
[
1251,
24,
832
],
[
832,
40,
888
]
],
[
[
1251,
63,
1594
],
[
1594,
40,
888
]
],
[
[
1251,
24,
543
],
[
543,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Tamoxifen (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Tamoxifen (Co... |
DB01059 | DB06603 | 956 | 39 | [
"DDInter1313",
"DDInter1387"
] | Norfloxacin | Panobinostat | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
956,
25,
39
]
],
[
[
956,
62,
112
],
[
112,
23,
39
]
],
[
[
956,
63,
455
],
[
455,
24,
39
]
],
[
[
956,
62,
869
],
[
869,
24,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and ... |
DB01592 | DB11943 | 1,596 | 255 | [
"DDInter975",
"DDInter495"
] | Iron | Delafloxacin | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
1596,
24,
255
]
],
[
[
1596,
63,
1283
],
[
1283,
24,
255
]
],
[
[
1596,
24,
286
],
[
286,
24,
255
]
],
[
[
1596,
62,
1096
],
[
1096,
... | [
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"... | Iron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin
Iron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide a... |
DB00222 | DB01319 | 245 | 34 | [
"DDInter825",
"DDInter777"
] | Glimepiride | Fosamprenavir | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
245,
24,
34
]
],
[
[
245,
24,
1091
],
[
1091,
40,
34
]
],
[
[
245,
21,
28723
],
[
28723,
60,
34
]
],
[
[
245,
24,
609
],
[
609,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Glimepiride (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Fosamprenavir (Compound)
Glimepiride may cause a modera... |
DB00694 | DB08873 | 51 | 74 | [
"DDInter485",
"DDInter221"
] | Daunorubicin | Boceprevir | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in... | Moderate | 1 | [
[
[
51,
24,
74
]
],
[
[
51,
7,
10499
],
[
10499,
45,
74
]
],
[
[
51,
6,
4973
],
[
4973,
45,
74
]
],
[
[
51,
21,
28769
],
[
28769,
60... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Boceprevir"
]
],
[
[
"Daunorubicin",
"{u} (Compound) upregulates {v} (Gene)",
"CTSV"
],
[
"CTSV",
"{u} (Gene) is bound by {v} (Compo... | Daunorubicin (Compound) upregulates CTSV (Gene) and CTSV (Gene) is bound by Boceprevir (Compound)
Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Boceprevir (Compound)
Daunorubicin (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Boceprevir (Compou... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.